• A Novel Dental Screening Scale for Tardive Dyskinesia Aims to Improve Detection

    By Gina ShawA new half-page screening checklist developed at The University of Texas Health Science Center (UTHealth) at Houston School of Dentistry aims to put tardive dyskinesia (TD) recognition into routine dental practice.The Dental–Abnormal Involuntary Movement Scale (D-AIMS), developed by June M. Sadowsky, DDS, MPH, and Ben F. Warner, MS, DDS, MD, both professors of dentistry at UTHealth, distills the orofacial elements of the standard Abnormal Involuntary Movement Scale (AIMS) into
  • How Will Deutetrabenazine Price Cut Affect Rx Access?

    By Gina ShawFor pharmacists who manage patients on antipsychotics, Medicare’s newly negotiated price for deutetrabenazine (Austedo/Austedo XR, Teva Pharmaceuticals) could have meaningful consequences for day-to-day patient access.The tardive dyskinesia (TD) medication is one of 15 drugs selected for the second round of Medicare Part D price negotiations under the Inflation Reduction Act (IRA). Beginning Jan. 1, 2027, its Medicare-negotiated maximum fair price (MFP) will be $4,093 for a 30-

Follow @newsl_pharmacy on Twitter!